Cargando…
Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England
The UK prioritised delivery of the first dose of BNT162b2 (Pfizer/BioNTech) and AZD1222 (AstraZeneca) vaccines by extending the interval between doses up to 12 weeks. In 750 participants aged 50–89 years, we here compare serological responses after BNT162b2 and AZD1222 vaccination with varying dose...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664823/ https://www.ncbi.nlm.nih.gov/pubmed/34893611 http://dx.doi.org/10.1038/s41467-021-27410-5 |
_version_ | 1784613923059662848 |
---|---|
author | Amirthalingam, Gayatri Bernal, Jamie Lopez Andrews, Nick J. Whitaker, Heather Gower, Charlotte Stowe, Julia Tessier, Elise Subbarao, Sathyavani Ireland, Georgina Baawuah, Frances Linley, Ezra Warrener, Lenesha O’Brien, Michelle Whillock, Corinne Moss, Paul Ladhani, Shamez N. Brown, Kevin E. Ramsay, Mary E. |
author_facet | Amirthalingam, Gayatri Bernal, Jamie Lopez Andrews, Nick J. Whitaker, Heather Gower, Charlotte Stowe, Julia Tessier, Elise Subbarao, Sathyavani Ireland, Georgina Baawuah, Frances Linley, Ezra Warrener, Lenesha O’Brien, Michelle Whillock, Corinne Moss, Paul Ladhani, Shamez N. Brown, Kevin E. Ramsay, Mary E. |
author_sort | Amirthalingam, Gayatri |
collection | PubMed |
description | The UK prioritised delivery of the first dose of BNT162b2 (Pfizer/BioNTech) and AZD1222 (AstraZeneca) vaccines by extending the interval between doses up to 12 weeks. In 750 participants aged 50–89 years, we here compare serological responses after BNT162b2 and AZD1222 vaccination with varying dose intervals, and evaluate these against real-world national vaccine effectiveness (VE) estimates against COVID-19 in England. We show that antibody levels 14–35 days after dose two are higher in BNT162b2 recipients with an extended vaccine interval (65–84 days) compared with those vaccinated with a standard (19–29 days) interval. Following the extended schedule, antibody levels were 6-fold higher at 14–35 days post dose 2 for BNT162b2 than AZD1222. For both vaccines, VE was higher across all age-groups from 14 days after dose two compared to one dose, but the magnitude varied with dose interval. Higher dose two VE was observed with >6 week interval between BNT162b2 doses compared to the standard schedule. Our findings suggest higher effectiveness against infection using an extended vaccine schedule. Given global vaccine constraints these results are relevant to policymakers. |
format | Online Article Text |
id | pubmed-8664823 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-86648232021-12-27 Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England Amirthalingam, Gayatri Bernal, Jamie Lopez Andrews, Nick J. Whitaker, Heather Gower, Charlotte Stowe, Julia Tessier, Elise Subbarao, Sathyavani Ireland, Georgina Baawuah, Frances Linley, Ezra Warrener, Lenesha O’Brien, Michelle Whillock, Corinne Moss, Paul Ladhani, Shamez N. Brown, Kevin E. Ramsay, Mary E. Nat Commun Article The UK prioritised delivery of the first dose of BNT162b2 (Pfizer/BioNTech) and AZD1222 (AstraZeneca) vaccines by extending the interval between doses up to 12 weeks. In 750 participants aged 50–89 years, we here compare serological responses after BNT162b2 and AZD1222 vaccination with varying dose intervals, and evaluate these against real-world national vaccine effectiveness (VE) estimates against COVID-19 in England. We show that antibody levels 14–35 days after dose two are higher in BNT162b2 recipients with an extended vaccine interval (65–84 days) compared with those vaccinated with a standard (19–29 days) interval. Following the extended schedule, antibody levels were 6-fold higher at 14–35 days post dose 2 for BNT162b2 than AZD1222. For both vaccines, VE was higher across all age-groups from 14 days after dose two compared to one dose, but the magnitude varied with dose interval. Higher dose two VE was observed with >6 week interval between BNT162b2 doses compared to the standard schedule. Our findings suggest higher effectiveness against infection using an extended vaccine schedule. Given global vaccine constraints these results are relevant to policymakers. Nature Publishing Group UK 2021-12-10 /pmc/articles/PMC8664823/ /pubmed/34893611 http://dx.doi.org/10.1038/s41467-021-27410-5 Text en © Crown 2021, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Amirthalingam, Gayatri Bernal, Jamie Lopez Andrews, Nick J. Whitaker, Heather Gower, Charlotte Stowe, Julia Tessier, Elise Subbarao, Sathyavani Ireland, Georgina Baawuah, Frances Linley, Ezra Warrener, Lenesha O’Brien, Michelle Whillock, Corinne Moss, Paul Ladhani, Shamez N. Brown, Kevin E. Ramsay, Mary E. Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England |
title | Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England |
title_full | Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England |
title_fullStr | Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England |
title_full_unstemmed | Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England |
title_short | Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England |
title_sort | serological responses and vaccine effectiveness for extended covid-19 vaccine schedules in england |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664823/ https://www.ncbi.nlm.nih.gov/pubmed/34893611 http://dx.doi.org/10.1038/s41467-021-27410-5 |
work_keys_str_mv | AT amirthalingamgayatri serologicalresponsesandvaccineeffectivenessforextendedcovid19vaccineschedulesinengland AT bernaljamielopez serologicalresponsesandvaccineeffectivenessforextendedcovid19vaccineschedulesinengland AT andrewsnickj serologicalresponsesandvaccineeffectivenessforextendedcovid19vaccineschedulesinengland AT whitakerheather serologicalresponsesandvaccineeffectivenessforextendedcovid19vaccineschedulesinengland AT gowercharlotte serologicalresponsesandvaccineeffectivenessforextendedcovid19vaccineschedulesinengland AT stowejulia serologicalresponsesandvaccineeffectivenessforextendedcovid19vaccineschedulesinengland AT tessierelise serologicalresponsesandvaccineeffectivenessforextendedcovid19vaccineschedulesinengland AT subbaraosathyavani serologicalresponsesandvaccineeffectivenessforextendedcovid19vaccineschedulesinengland AT irelandgeorgina serologicalresponsesandvaccineeffectivenessforextendedcovid19vaccineschedulesinengland AT baawuahfrances serologicalresponsesandvaccineeffectivenessforextendedcovid19vaccineschedulesinengland AT linleyezra serologicalresponsesandvaccineeffectivenessforextendedcovid19vaccineschedulesinengland AT warrenerlenesha serologicalresponsesandvaccineeffectivenessforextendedcovid19vaccineschedulesinengland AT obrienmichelle serologicalresponsesandvaccineeffectivenessforextendedcovid19vaccineschedulesinengland AT whillockcorinne serologicalresponsesandvaccineeffectivenessforextendedcovid19vaccineschedulesinengland AT mosspaul serologicalresponsesandvaccineeffectivenessforextendedcovid19vaccineschedulesinengland AT ladhanishamezn serologicalresponsesandvaccineeffectivenessforextendedcovid19vaccineschedulesinengland AT brownkevine serologicalresponsesandvaccineeffectivenessforextendedcovid19vaccineschedulesinengland AT ramsaymarye serologicalresponsesandvaccineeffectivenessforextendedcovid19vaccineschedulesinengland |